GPGI Q3 2026 In-Line but Cuts FY26 Guidance on Husky Margin Headwinds

What happened

GPGI reported Q3 2026 pro forma adjusted net sales of $509.6 million, up 4.5% year-over-year, with net income of $76.0 million, in line with expectations. Strength at CompoSecure and improving demand at Husky drove the quarter, but management lowered full-year 2026 guidance due to margin headwinds at Husky, partially offset by continued strength at CompoSecure. For Q4 2026, the company expects sequential strength with low single-digit organic revenue growth and high single-digit adjusted EBITDA growth at the midpoint. Management anticipates a return to its growth algorithm in 2027, citing acceleration in Husky's pipeline, orders, and recurring aftermarket. This update suggests Husky integration is progressing slower than initially hoped, but CompoSecure remains resilient, keeping the combined business on a path to potentially meet reduced expectations.

Implication

The reduced FY26 guidance, driven by Husky margins, validates the bear case outlined in our base analysis where Husky EBITDA margins compress toward 22-23%, pressuring combined EBITDA below the $635 million deal-deck target. While CompoSecure's strength provides a partial offset, the overall thesis now carries higher execution risk, and the current valuation around 11.6x 2026E adjusted EBITDA leaves little room for error. Investors should monitor Husky's margin trajectory and orders in coming quarters; if margin compression persists without credible remediation, the stock could de-rate toward our bear-case fair value of $18. Conversely, if Q4 2026 shows the expected strong sequential improvement and 2027 orders confirm acceleration, the stock may hold near base-case fair value of $24, but upside beyond $30 appears limited given the crowded long positioning. Until there is clearer evidence that Husky can stabilize margins and the combined entity can deleverage below 3.5x, we recommend trimming positions above $30 and awaiting a pullback toward $20 for a more attractive risk-reward.

Thesis delta

The new information shifts our thesis marginally more negative: the explicit acknowledgment of Husky margin headwinds and revised FY26 guidance align with the bear case we highlighted, where Husky EBITDA margins settle near 22-23% rather than the 25-26% assumed in the deal deck. This reduces confidence in achieving the ~$635M 2026 EBITDA target and suggests the combined entity may underperform initial pro forma projections. However, continued strength at CompoSecure and the expected return to growth algorithm in 2027 keep the base case of ~$600M EBITDA and ~$24 fair value intact, pending further evidence.